

## Test report

**Date:** Dec. 16th 2020.

**Assignment:**

Assessment of the effect of UV BARx1 against SARS-CoV-2 viability

**Attendees:**

Assoc. Prof. PhD Thomas Emil Andersen, Research Assistant BSc Ditte Sandfelt Tornby, Biomedical Scientist MSc Line Bang.

**Time period for test work:**

Dec.10th-15th 2020.

**Task description:**

Single measurements of the viability of SARS-CoV-2 after 2, 4 and 8 seconds exposure at distances of 50 and 100mm.

**Day one:** Culturing of host cells (VERO C1008 [Vero 76, clone E6, Vero E6] (ATCC® CRL-1586™).

**Day two:** Preparation of experiment, irradiation of test specimens, infection of VERO E6 cells and establishment of plaque assay.

**Day five:** Termination of plaque assay, collection of data.

**Protocol:**

$2 \times 10^6$  pfu/mL SARS-CoV-2 stock is diluted to  $10^2$  i prewarmed ( $37^\circ\text{C}$ ) DMEM 2% (+Amp. B og PenStrep). 400 $\mu\text{L}$  is transferred to the center of a sterile 6-well microtiter plate and exposed to UV BARx1 UV-light for 2, 4 og 8 seconds at distances 50 og 100mm (Figure 1-3). All treatments were conducted separately in time and space. 300 $\mu\text{L}$  of treated viral suspension is transferred to 6-well plate with 24h confluent VERO E6 cell cultures, incubated for 1h on tipping table at  $37^\circ\text{C}/5\% \text{CO}_2$ , agar overlaid and plaque assay established.

**Results, UV BARx1: surviving virions relative to total treated virions:**

distance\exposure time	2 seconds	4 seconds	8 seconds
50mm	0/6 x $10^3$	0/6 x $10^3$	0/6 x $10^3$
100mm	0/6 x $10^3$	0/6 x $10^3$	0/6 x $10^3$

**Conclusion:** virions are inactivated at all exposure times/distances to below the detection level, i.e. a  $>\log_3$  or  $>99,9\%$  reduction in active virions.

Figures:




Figure 1. Experimental setup.




Figure 2. Experimental setup.




Figure 3. Experimental setup.




Figure 4. Plaque assay of untreated viral stock cultured in triplicates at  $10^4$  dilution (top row) and  $10^5$  dilution (bottom row). 300ul stock solution is added per well.





Figure 5. Plaque assay conducted with viral suspensions exposed to UV treatment (UV BARx1). The viral suspension was diluted  $10^2$  prior to treatment corresponding to  $6 \times 10^3$  pfu/300  $\mu$ L/brønd. No plaques i.e. viable virions could be detected upon treatment-meaning  $>\log_3$  or  $>99,9\%$  reduction i viable virions.



**Thomas Emil Andersen**  
Senior Researcher, Assoc. Prof., Ph.D.  
Dept. of Clinical Microbiology  
**Odense University Hospital**  
J.B. Winsløvs Vej 21, 2.  
DK-5000 Odense C  
Phone: +45 21 26 16 34